Subtopic Deep Dive
Fecal Microbiota Transplantation for C. difficile
Research Guide
What is Fecal Microbiota Transplantation for C. difficile?
Fecal Microbiota Transplantation (FMT) is the transfer of fecal microorganisms from a healthy donor into the gastrointestinal tract of a patient to restore gut microbiota balance for treating recurrent Clostridium difficile infection.
FMT achieves cure rates over 90% for recurrent C. difficile infections, outperforming vancomycin as shown in a randomized trial (van Nood et al., 2013, 3574 citations). Guidelines from IDSA/SHEA recommend FMT after multiple recurrences (McDonald et al., 2018, 1115 citations). European consensus supports standardized FMT protocols (Cammarota et al., 2017, 1092 citations).
Why It Matters
FMT treats recurrent C. difficile infections resistant to antibiotics, reducing relapse rates and healthcare costs in clinical settings (van Nood et al., 2013). Donor selection and engraftment mechanisms influence long-term efficacy, informing protocols for broader dysbiosis applications (Cammarota et al., 2017). Safety risks, such as drug-resistant pathogen transmission, highlight needs for screening (DeFilipp et al., 2019). IDSA/SHEA guidelines integrate FMT into standard care, impacting hospital infection control (McDonald et al., 2018).
Key Research Challenges
Donor Selection Risks
Screening donors for pathogens like extended-spectrum beta-lactamase E. coli is critical to prevent transmission during FMT (DeFilipp et al., 2019). Variability in donor microbiota affects engraftment success. Standardized criteria remain under development (Cammarota et al., 2017).
Microbiota Engraftment Mechanisms
Understanding how transplanted microbes colonize and suppress C. difficile requires longitudinal studies. Factors like PPI use alter microbiome composition, impacting FMT outcomes (Imhann et al., 2015). Meta-analyses identify shared microbial responses across diseases (Duvallet et al., 2017).
Standardized Delivery Protocols
Methods vary from duodenal infusion to colonoscopy, complicating comparisons (van Nood et al., 2013). Regulatory approval demands consistent safety and efficacy data (McDonald et al., 2018). Stool substitutes offer alternatives but need validation (Petrof et al., 2013).
Essential Papers
Duodenal Infusion of Donor Feces for Recurrent <i>Clostridium difficile</i>
Els van Nood, Anne Vrieze, Max Nieuwdorp et al. · 2013 · New England Journal of Medicine · 3.6K citations
The infusion of donor feces was significantly more effective for the treatment of recurrent C. difficile infection than the use of vancomycin. (Funded by the Netherlands Organization for Health Res...
Microbiota in health and diseases
Kejun Hou, Zhuo‐Xun Wu, Xuan-Yu Chen et al. · 2022 · Signal Transduction and Targeted Therapy · 2.6K citations
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Aleksandar D. Kostic, Ramnik J. Xavier, Dirk Gevers · 2014 · Gastroenterology · 1.7K citations
Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study
Dae‐Wook Kang, James B. Adams, Ann Gregory et al. · 2017 · Microbiome · 1.3K citations
Proton pump inhibitors affect the gut microbiome
Floris Imhann, Marc Jan Bonder, Arnau Vich Vila et al. · 2015 · Gut · 1.3K citations
Background and aims Proton pump inhibitors (PPIs) are among the top 10 most widely used drugs in the world. PPI use has been associated with an increased risk of enteric infections, most notably Cl...
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
L. Clifford McDonald, Dale N. Gerding, Stuart Johnson et al. · 2018 · Clinical Infectious Diseases · 1.1K citations
Abstract A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guidelin...
European consensus conference on faecal microbiota transplantation in clinical practice
Giovanni Cammarota, Gianluca Ianiro, Herbert Tilg et al. · 2017 · Gut · 1.1K citations
Faecal microbiota transplantation (FMT) is an important therapeutic option for Clostridium difficile infection. Promising findings suggest that FMT may play a role also in the management of other d...
Reading Guide
Foundational Papers
Start with van Nood et al. (2013, 3574 citations) for RCT evidence of FMT superiority over vancomycin. Follow with Petrof et al. (2013) on stool substitutes as safer alternatives.
Recent Advances
Study McDonald et al. (2018) IDSA/SHEA guidelines for clinical integration. Review Cammarota et al. (2017) consensus and DeFilipp et al. (2019) on transmission risks.
Core Methods
Core techniques include donor screening, 16S rRNA sequencing for engraftment (Duvallet et al., 2017), duodenal infusion (van Nood et al., 2013), and meta-analysis of microbiome shifts (Imhann et al., 2015).
How PapersFlow Helps You Research Fecal Microbiota Transplantation for C. difficile
Discover & Search
Research Agent uses searchPapers and citationGraph to map FMT efficacy from van Nood et al. (2013) to guidelines like McDonald et al. (2018), revealing 3574 citations and descendants. exaSearch finds protocol variations; findSimilarPapers clusters donor risk papers like DeFilipp et al. (2019).
Analyze & Verify
Analysis Agent applies readPaperContent to extract engraftment data from Cammarota et al. (2017), then verifyResponse with CoVe checks claims against IDSA guidelines (McDonald et al., 2018). runPythonAnalysis performs GRADE grading on cure rates from van Nood et al. (2013) and statistical meta-analysis of recurrence data.
Synthesize & Write
Synthesis Agent detects gaps in long-term safety post-FMT, flags contradictions between PPI effects (Imhann et al., 2015) and engraftment. Writing Agent uses latexEditText for protocol drafts, latexSyncCitations for van Nood references, latexCompile for reports, and exportMermaid for microbiota engraftment diagrams.
Use Cases
"Analyze cure rates and recurrence in FMT trials for C. difficile using Python meta-analysis."
Research Agent → searchPapers (FMT C. difficile) → Analysis Agent → readPaperContent (van Nood 2013, McDonald 2018) → runPythonAnalysis (pandas meta-analysis of 90%+ cure rates, matplotlib forest plot) → researcher gets CSV of pooled odds ratios.
"Draft LaTeX review on FMT protocols citing van Nood and Cammarota."
Synthesis Agent → gap detection (protocol standardization) → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (10 papers) → latexCompile → researcher gets PDF with formatted references and tables.
"Find code for microbiota analysis in FMT engraftment studies."
Research Agent → citationGraph (Cammarota 2017) → paperFindGithubRepo → githubRepoInspect (QIIME2 pipelines for alpha diversity) → researcher gets annotated R scripts for 16S sequencing from Duvallet et al. (2017) supplements.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (FMT C. difficile, 50+ papers) → citationGraph → GRADE via Analysis Agent → structured report on efficacy (van Nood et al., 2013). DeepScan applies 7-step verification with CoVe on donor risks (DeFilipp et al., 2019). Theorizer generates hypotheses on PPI-FMT interactions from Imhann et al. (2015).
Frequently Asked Questions
What is Fecal Microbiota Transplantation for C. difficile?
FMT transfers donor feces via duodenal infusion or colonoscopy to treat recurrent C. difficile by restoring microbiota (van Nood et al., 2013). It achieves 90%+ cure rates versus vancomycin.
What are key methods in FMT research?
Duodenal infusion proved superior in RCTs (van Nood et al., 2013). Guidelines recommend post-failed antibiotics (McDonald et al., 2018). Consensus details nasogastric, enema, or capsule delivery (Cammarota et al., 2017).
What are key papers on FMT for C. difficile?
van Nood et al. (2013, NEJM, 3574 citations) showed FMT efficacy. McDonald et al. (2018, IDSA/SHEA) updated guidelines. Cammarota et al. (2017, Gut) provided European consensus.
What are open problems in FMT for C. difficile?
Pathogen transmission risks persist despite screening (DeFilipp et al., 2019). Long-term engraftment mechanisms unclear. Standardized donor banks and oral formulations need validation (Petrof et al., 2013).
Research Clostridium difficile and Clostridium perfringens research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Fecal Microbiota Transplantation for C. difficile with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers